Patents by Inventor David Hockenbery

David Hockenbery has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220125814
    Abstract: Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor in combination with a nicotinamide adenine dinucleotide (NAD) salvage pathway precursor are described. Cancers treated with the combination therapies can be nicotinamide riboside kinase (NMRK1) low cancers and/or Myc high cancers and can include various forms of glioblastomas.
    Type: Application
    Filed: March 20, 2020
    Publication date: April 28, 2022
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: David Hockenbery, Patrick Paddison
  • Patent number: 8865901
    Abstract: Compounds are described that are useful for treating an apoptosis-associated disease, which are specifically cytotoxic to tumor cells that are overexpressing Bcl-xL, and are much less cytotoxic in isogenic cells that are not overexpressing Bcl-xL. Also described is a method for treating an apoptosis-associated disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an active compound that is specifically cytotoxic to tumor cells that are overexpressing Bcl-xL, and are much less cytotoxic in isogenic cells that are not overexpressing Bcl-xL. Several scaffolds of active compounds are described.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: October 21, 2014
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: David Hockenbery, Julian Simon
  • Publication number: 20120252839
    Abstract: Compounds are described that are useful for treating an apoptosis-associated disease, which are specifically cytotoxic to tumor cells that are overexpressing Bcl-xL, and are much less cytotoxic in isogenic cells that are not overexpressing Bcl-xL. Also described is a method for treating an apoptosis-associated disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an active compound that is specifically cytotoxic to tumor cells that are overexpressing Bcl-xL, and are much less cytotoxic in isogenic cells that are not overexpressing Bcl-xL. Several scaffolds of active compounds are described.
    Type: Application
    Filed: April 2, 2012
    Publication date: October 4, 2012
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: David HOCKENBERY, Julian SIMON
  • Publication number: 20060188948
    Abstract: The present invention provides methods and combinations of methods for identifying agents that modulate the apoptotic state of a cell by binding to the hydrophobic groove of a Bcl-2 family member anti-apoptotic protein. In certain embodiments, the methods generally comprise the use of Bcl-2 family member proteins having one or more mutations in the hydrophobic groove that, relative to a corresponding protein lacking the mutation, affect, e.g., binding of desired agents or in vitro antimycin sensitivity without substantially altering tertiary protein structure. In these embodiments, the methods comprise the identification of agents that exhibit reduced binding affinities and/or other biological activities for the mutant proteins relative to the corresponding Bcl-2 family member lacking the mutation.
    Type: Application
    Filed: January 13, 2006
    Publication date: August 24, 2006
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: David Hockenbery, Michael Manion
  • Publication number: 20050239873
    Abstract: Disclosed are 2-methoxy antimycin derivatives or analogs that modulate apoptosis by binding to the hydrophobic groove of a Bcl-2 family member protein (e.g., Bcl-2 or BCl-xL). The 2-methoxy antimycin derivatives or analogs are used in disclosed methods for treating apoptosis-associated diseases such as, for example, neoplastic disease (e.g., cancer) or other proliferative diseases associated with the over-expression of a Bcl-2 family member protein.
    Type: Application
    Filed: January 14, 2005
    Publication date: October 27, 2005
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: David Hockenbery, Julian Simon, Shie-Pon Tzung